HMG-CoA reductase inhibitor fluvastatin prevents angiotensin II-induced cardiac hypertrophy via Rho kinase and inhibition of cyclin D1.

[1]  K. Akashi,et al.  Mouse Development and Cell Proliferation in the Absence of D-Cyclins , 2004, Cell.

[2]  A. Takeshita,et al.  Long-Term Inhibition of Rho-Kinase Suppresses Angiotensin II–Induced Cardiovascular Hypertrophy in Rats In Vivo: Effect on Endothelial NAD(P)H Oxidase System , 2003, Circulation research.

[3]  Xiaodong Yang,et al.  HEPN1, a novel gene that is frequently down-regulated in hepatocellular carcinoma, suppresses cell growth and induces apoptosis in HepG2 cells. , 2003, Journal of hepatology.

[4]  Kazuo Ichihara,et al.  All hydrophobic HMG-CoA reductase inhibitors induce apoptotic death in rat pulmonary vein endothelial cells. , 2003, Atherosclerosis.

[5]  M. Isobe,et al.  Nitric oxide inhibits ischemia/reperfusion-induced myocardial apoptosis by modulating cyclin A-associated kinase activity. , 2003, Cardiovascular research.

[6]  S. Rivkees,et al.  Rho‐associated kinases play an essential role in cardiac morphogenesis and cardiomyocyte proliferation , 2003, Developmental dynamics : an official publication of the American Association of Anatomists.

[7]  K. Akimoto,et al.  Cerivastatin, a hydroxymethylglutaryl coenzyme A reductase inhibitor, inhibits cardiac myocyte hypertrophy induced by endothelin. , 2002, European journal of pharmacology.

[8]  A. Curcio,et al.  Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor Simvastatin Prevents Cardiac Hypertrophy Induced by Pressure Overload and Inhibits p21 ras Activation , 2002, Circulation.

[9]  M. Ikeda,et al.  Expression of cyclin D1 and CDK4 causes hypertrophic growth of cardiomyocytes in culture: a possible implication for cardiac hypertrophy. , 2002, Biochemical and biophysical research communications.

[10]  S. Fukushima,et al.  Formation of 8-hydroxydeoxyguanosine and cell-cycle arrest in the rat liver via generation of oxidative stress by phenobarbital: association with expression profiles of p21(WAF1/Cip1), cyclin D1 and Ogg1. , 2002, Carcinogenesis.

[11]  K. Node,et al.  Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. , 2001, The Journal of clinical investigation.

[12]  M. Schwartz,et al.  Timing of cyclin D1 expression within G1 phase is controlled by Rho , 2001, Nature Cell Biology.

[13]  M. Ikeda,et al.  Cyclin A/cdk2 Activation Is Involved in Hypoxia-Induced Apoptosis in Cardiomyocytes , 2001, Circulation research.

[14]  A. Clerk,et al.  Small guanine nucleotide-binding proteins and myocardial hypertrophy. , 2000, Circulation research.

[15]  F. Marumo,et al.  G1 cyclins are involved in the mechanism of cardiac myocyte hypertrophy induced by angiotensin II. , 2000, Japanese circulation journal.

[16]  Xiaohang Zhao,et al.  Direct inhibition of G1 cdk kinase activity by MyoD promotes myoblast cell cycle withdrawal and terminal differentiation , 1999, The EMBO journal.

[17]  U. Laufs,et al.  3-Hydroxy-3-methylglutaryl-CoA Reductase Inhibitors Attenuate Vascular Smooth Muscle Proliferation by Preventing Rho GTPase-induced Down-regulation of p27 Kip1 * , 1999, The Journal of Biological Chemistry.

[18]  J. Kawabe,et al.  Lovastatin prevents angiotensin II-induced cardiac hypertrophy in cultured neonatal rat heart cells. , 1999, European journal of pharmacology.

[19]  B. Kasiske,et al.  Effects of lovastatin on expression of cell cycle regulatory proteins in vascular smooth muscle cells. , 1999, Kidney international. Supplement.

[20]  M. Ikeda,et al.  Essential roles for G1cyclin-dependent kinase activity in development of cardiomyocyte hypertrophy. , 1998, American journal of physiology. Heart and circulatory physiology.

[21]  C. Sirtori,et al.  Direct effects of statins on the vascular wall. , 1998, Journal of cardiovascular pharmacology.

[22]  J. Sadoshima,et al.  Angiotensin II activates RhoA in cardiac myocytes: a critical role of RhoA in angiotensin II-induced premyofibril formation. , 1998, Circulation research.

[23]  F. Bernini,et al.  Direct vascular effects of HMG-CoA reductase inhibitors. , 1997, Atherosclerosis.

[24]  J. Sadoshima,et al.  Angiotensin II and serum differentially regulate expression of cyclins, activity of cyclin-dependent kinases, and phosphorylation of retinoblastoma gene product in neonatal cardiac myocytes. , 1997, Circulation research.

[25]  Nobuyuki Shishido,et al.  Mice Lacking p27 Kip1 Display Increased Body Size, Multiple Organ Hyperplasia, Retinal Dysplasia, and Pituitary Tumors , 1996, Cell.

[26]  B. Kasiske,et al.  Inhibition of the mevalonate pathway: benefits beyond cholesterol reduction? , 1996, The Lancet.

[27]  A. Zantema,et al.  Cyclin D1 is an essential mediator of apoptotic neuronal cell death. , 1996, The EMBO journal.

[28]  F. Tse,et al.  Pharmacokinetics of Fluvastatin After Single and Multiple Doses in Normal Volunteers , 1992, Journal of clinical pharmacology.

[29]  W. Koch,et al.  Genetic Alterations That Inhibit In Vivo Pressure-Overload Hypertrophy Prevent Cardiac Dysfunction Despite Increased Wall Stress , 2002, Circulation.

[30]  N. Tapon,et al.  Rho, Rac and Cdc42 GTPases regulate the organization of the actin cytoskeleton. , 1997, Current opinion in cell biology.